Fentanyl

Generic Name
Fentanyl
Brand Names
Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys, PecFent
Drug Type
Small Molecule
Chemical Formula
C22H28N2O
CAS Number
437-38-7
Unique Ingredient Identifier
UF599785JZ
Background

Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone.

Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily.

Fentanyl was FDA approved in 1968.

Indication

Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.

Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.

Associated Conditions
Cancer Related Pain (Breakthrough Pain), Severe, Chronic Pain
Associated Therapies
Anesthetic premedication therapy, Anesthetics Agent, General Anesthesia, Induction of anesthesia therapy, Maintenance of anesthesia therapy, Regional Anesthesia therapy

RCT Evaluating Intranasal Fentanyl in the Pain Management of Children With Headaches

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2015-12-23
Last Posted Date
2020-09-03
Lead Sponsor
St. Justine's Hospital
Target Recruit Count
62
Registration Number
NCT02638506
Locations
🇨🇦

CHU Ste-Justine, Montreal, Quebec, Canada

Analgesic Effects of Midazolam in Human Volunteers

First Posted Date
2015-12-14
Last Posted Date
2016-03-11
Lead Sponsor
Wilhelminenspital Vienna
Target Recruit Count
24
Registration Number
NCT02629146
Locations
🇦🇹

Schmerzdiagnostik / Clinical Research Unit, Vienna, Austria

Remifentanil and Fentanyl in Dental Surgery (REFEDS)

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2015-12-02
Last Posted Date
2015-12-02
Lead Sponsor
Attikon Hospital
Target Recruit Count
46
Registration Number
NCT02619032
Locations
🇬🇷

2nd Department of Anesthesiology, Attikon University Hospital, Athens, Attiki, Greece

Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-12-01
Last Posted Date
2018-03-29
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
56
Registration Number
NCT02617758

Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection

First Posted Date
2015-11-30
Last Posted Date
2016-10-11
Lead Sponsor
University Medical Centre Ljubljana
Target Recruit Count
60
Registration Number
NCT02616523

Does Optimized General Anesthesia Care Reduce Postoperative Delirium?

First Posted Date
2015-11-13
Last Posted Date
2023-10-17
Lead Sponsor
University of Missouri-Columbia
Target Recruit Count
145
Registration Number
NCT02604459
Locations
🇺🇸

University of Missouri Hospitals, Columbia, Missouri, United States

The Pharmacokinetics of Fentanyl in Intensive Care Patients

First Posted Date
2015-10-27
Last Posted Date
2015-10-29
Lead Sponsor
Oslo University Hospital
Target Recruit Count
150
Registration Number
NCT02587273
Locations
🇳🇴

Oslo University Hospital, Ullevål, Oslo, Norway

© Copyright 2024. All Rights Reserved by MedPath